BiotechTube
Aquilon Pharmaceuticals

Aquilon Pharmaceuticals

Ghent, Belgium· Est.
aquilonpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Aquilon Pharmaceuticals is a private, clinical-stage biotech leveraging its proprietary HP-Betadex excipient platform to revolutionize inhaled drug delivery. The company aims to enhance the pharmacology and lung deposition of drugs for respiratory diseases, with a pipeline progressing through clinical trials. With strong academic roots and recent €6 million refinancing, Aquilon is positioning for the commercial launch of its nasal product line while advancing its dry powder inhaler formulations.

AsthmaCOPDNasal Conditions

Technology Platform

Proprietary HP-Betadex (Hydroxypropyl-Betadex) excipient platform designed to improve lung deposition and local bioavailability of inhaled drugs. The technology is compatible with all inhalation devices.

Opportunities

The large and growing global market for inhaled respiratory drugs presents a major opportunity for a platform that can demonstrably improve efficacy and deposition.
The device-agnostic nature of the technology lowers barriers to adoption and facilitates partnerships with existing drug and device companies.
The near-term launch of a nasal product line provides a path to initial revenue and market validation.

Risk Factors

The company faces development and regulatory risks associated with bringing new pharmaceutical formulations to market.
Its financial runway may be limited post the €6 million raise, requiring additional funding for full pipeline development.
It operates in a highly competitive drug delivery landscape with numerous established and emerging technologies.

Competitive Landscape

Aquilon competes in the advanced drug formulation and pulmonary delivery space, which includes large specialty pharma companies (e.g., Vectura, Aptar), generic inhaler developers, and numerous biotech startups focused on novel excipients or particle engineering. Its differentiation lies in the specific application of HP-Betadex for inhalation and its focus on improving existing drugs rather than developing new molecular entities.

More companies in Drug Delivery & Formulation →More companies in Belgium →